title: Could immunosignatures technology enable the development of a preventative cancer vaccine?
abstract: The exciting prospect of developing a universal prophylactic cancer vaccine now seems more possible due to advances in technology and basic knowledge. However, the problem of testing the efficacy of such a vaccine in a clinical trial seems daunting. The low incidence and long lead-time to diagnosis of cancer would make a standard clinical trial long and expensive. Recently, we demonstrated that the immunosignatures diagnostic technology could be useful in evaluating vaccines. The technology is based on profiling the antibody diversity in an individual on a peptide chip platform. Here we propose that this technology may also enable a clinical trial of a preventative vaccine. Preliminary evidence supports the prospect of immunosignatures detecting cancer at very early stages, well before conventional diagnosis. Because the technology is simple and inexpensive, it could be used to monitor the occurrence of cancer in participants and shorten the clinical trial.
authors.affiliation: Center for Innovations in Medicine, Biodesign Institute, Arizona State University, 1001 South McAllister Avenue, Tempe, AZ 85287, USA.
authors.forename: Luhui
authors.initials: L
authors.lastname: Shen
authors.forename: Debra Tumbula
authors.initials: DT
authors.lastname: Hansen
authors.forename: Stephen Albert
authors.initials: SA
authors.lastname: Johnston
authors.forename: Joseph Barten
authors.initials: JB
authors.lastname: Legutki
mesh_terms: D000912:Antibodies, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D009369:Neoplasms / Q000276:immunology* / Q000517:prevention & control*
chemical_list: D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines